Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018.
Obra : Frontiers in Endocrinology

Idioma : Inglés (eng)

Palabras clave :	Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide
Resumen :	Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.
Mención de responsabilidad :	Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs
Referencia :	Front Endocrinol (Lausanne). 2018 Jun 15;9:318
DOI (Digital Object Identifier) :	10.3389/fendo.2018.00318
PMID :	29963012
En línea :	https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163